Your browser doesn't support javascript.
loading
An ultrapotent RBD-targeted biparatopic nanobody neutralizes broad SARS-CoV-2 variants.
Chi, Xiaojing; Zhang, Xinhui; Pan, Shengnan; Yu, Yanying; Shi, Yujin; Lin, Tianli; Duan, Huarui; Liu, Xiuying; Chen, Wenfang; Yang, Xuehua; Chen, Lan; Dong, Xiaoqian; Ren, Lili; Ding, Qiang; Wang, Jianwei; Yang, Wei.
Afiliação
  • Chi X; NHC Key Laboratory of Systems Biology of Pathogens, Institute of Pathogen Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, 100176, Beijing, China.
  • Zhang X; NHC Key Laboratory of Systems Biology of Pathogens, Institute of Pathogen Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, 100176, Beijing, China.
  • Pan S; NHC Key Laboratory of Systems Biology of Pathogens, Institute of Pathogen Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, 100176, Beijing, China.
  • Yu Y; School of Medicine, Tsinghua University, 100084, Beijing, China.
  • Shi Y; NHC Key Laboratory of Systems Biology of Pathogens, Institute of Pathogen Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, 100176, Beijing, China.
  • Lin T; NHC Key Laboratory of Systems Biology of Pathogens, Institute of Pathogen Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, 100176, Beijing, China.
  • Duan H; NHC Key Laboratory of Systems Biology of Pathogens, Institute of Pathogen Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, 100176, Beijing, China.
  • Liu X; NHC Key Laboratory of Systems Biology of Pathogens, Institute of Pathogen Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, 100176, Beijing, China.
  • Chen W; NHC Key Laboratory of Systems Biology of Pathogens, Institute of Pathogen Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, 100176, Beijing, China.
  • Yang X; NHC Key Laboratory of Systems Biology of Pathogens, Institute of Pathogen Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, 100176, Beijing, China.
  • Chen L; NHC Key Laboratory of Systems Biology of Pathogens, Institute of Pathogen Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, 100176, Beijing, China.
  • Dong X; NHC Key Laboratory of Systems Biology of Pathogens, Institute of Pathogen Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, 100176, Beijing, China.
  • Ren L; NHC Key Laboratory of Systems Biology of Pathogens, Institute of Pathogen Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, 100176, Beijing, China.
  • Ding Q; School of Medicine, Tsinghua University, 100084, Beijing, China. qding@tsinghua.edu.cn.
  • Wang J; NHC Key Laboratory of Systems Biology of Pathogens, Institute of Pathogen Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, 100176, Beijing, China. wangjw28@163.com.
  • Yang W; NHC Key Laboratory of Systems Biology of Pathogens, Institute of Pathogen Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, 100176, Beijing, China. wyang@ipb.pumc.edu.cn.
Signal Transduct Target Ther ; 7(1): 44, 2022 02 09.
Article em En | MEDLINE | ID: mdl-35140196
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Proteínas Recombinantes de Fusão / Fragmentos Fc das Imunoglobulinas / Anticorpos Neutralizantes / Anticorpos de Domínio Único / SARS-CoV-2 / Anticorpos Antivirais Limite: Humans Idioma: En Revista: Signal Transduct Target Ther Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China País de publicação: Reino Unido
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Proteínas Recombinantes de Fusão / Fragmentos Fc das Imunoglobulinas / Anticorpos Neutralizantes / Anticorpos de Domínio Único / SARS-CoV-2 / Anticorpos Antivirais Limite: Humans Idioma: En Revista: Signal Transduct Target Ther Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China País de publicação: Reino Unido